Boston Scientific Corporation vs iShares MSCI Japan ETF — how do they compare? Boston Scientific Corporation trades at $43.58 (market cap $66.37B), while iShares MSCI Japan ETF trades at $93.24. The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | EWJ | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $96.97 |
52-Week Low | $42.63 | $71.69 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
EWJ, the iShares MSCI Japan ETF, trades at $92.72, down 1.94% on the day. Technical indicators are mixed, with a neutral overall signal but bullish moving averages, while key financial ratios are unavailable. The ETF provides exposure to Japanese equities but faces headwinds from yen weakness, as recent news highlights currency hedging strategies and potential government intervention to support the yen.
The outlook for EWJ is influenced by Japan's equity market performance and currency dynamics. Opportunities include diversification benefits and potential gains if the Nikkei 225 rebounds, but risks stem from yen depreciation, geopolitical tensions, and domestic economic policies. Investors should weigh currency-hedged alternatives amid ongoing volatility.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →